A334970 Stock Overview
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Prestige Biologics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,160.00 |
| 52 Week High | ₩5,550.00 |
| 52 Week Low | ₩3,850.00 |
| Beta | 1.21 |
| 1 Month Change | -7.66% |
| 3 Month Change | 2.84% |
| 1 Year Change | -6.83% |
| 3 Year Change | -76.36% |
| 5 Year Change | n/a |
| Change since IPO | -70.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| A334970 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.2% | 0.3% | -0.4% |
| 1Y | -6.8% | 5.7% | 4.5% |
Return vs Industry: A334970 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A334970 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A334970 volatility | |
|---|---|
| A334970 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A334970 has not had significant price volatility in the past 3 months.
Volatility Over Time: A334970's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | pbpharma.co.kr |
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd.
Prestige Biologics Co., Ltd. Fundamentals Summary
| A334970 fundamental statistics | |
|---|---|
| Market cap | ₩255.85b |
| Earnings (TTM) | -₩39.44b |
| Revenue (TTM) | ₩1.75b |
146.5x
P/S Ratio-6.5x
P/E RatioIs A334970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A334970 income statement (TTM) | |
|---|---|
| Revenue | ₩1.75b |
| Cost of Revenue | ₩1.25b |
| Gross Profit | ₩493.75m |
| Other Expenses | ₩39.94b |
| Earnings | -₩39.44b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -641.31 |
| Gross Margin | 28.28% |
| Net Profit Margin | -2,259.19% |
| Debt/Equity Ratio | 160.3% |
How did A334970 perform over the long term?
See historical performance and comparison